Neumora Therapeutics (NMRA) Expected to Announce Earnings on Monday

Neumora Therapeutics (NASDAQ:NMRA) is anticipated to announce its Q1 2025 earnings results after the market closes on Monday, May 12th. Analysts expect Neumora Therapeutics to post earnings of ($0.40) per share for the quarter.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.09. On average, analysts expect Neumora Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Neumora Therapeutics Stock Up 3.8 %

NMRA stock opened at $0.66 on Friday. The stock has a market capitalization of $107.21 million, a price-to-earnings ratio of -0.35 and a beta of 2.96. Neumora Therapeutics has a 52-week low of $0.62 and a 52-week high of $17.19. The stock’s fifty day simple moving average is $0.92 and its 200-day simple moving average is $4.75.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. HC Wainwright decreased their price target on Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. Guggenheim downgraded shares of Neumora Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, March 7th. William Blair lowered shares of Neumora Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, March 10th. Royal Bank of Canada reissued a “sector perform” rating and set a $4.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. Finally, Stifel Nicolaus downgraded Neumora Therapeutics from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $6.00 to $2.00 in a report on Friday, March 7th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $9.29.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.